Prof Grant McArthur speaks to ecancer about the latest results from the IMspire150 trial which aims to evaluate the use of atezolizumab, cobimetinib and vemurafenib in previously untreated patients with BRAFV600 mutation-positive advanced melanoma.

He outlines the biological rationale behind this study, in which duration of response to BRAF and MEK inhibition could be improved with the addition of an anti-PDL1 agent.

Prof McArthur also discusses the results of the trial, stating that progression-free survival was improved in the triplet arm compared to the doublet arm of the trial.

Although analysis for overall survival is ongoing, Prof McArthur mentions there is a trend favouring the use of the triplet combination in this respect.